Ricevi le ultime notizie sulle azioni UroGen Pharma con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di URGN

Ultime notizie per

UroGen Pharma

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

cancer

Biotech

News

Health Care

Movers

General

URGN

La FDA approva una terapia innovativa per un tumore ricorrente. Un gel che potrebbe mandare in pensione il bisturi per i pazienti.

Cancro alla vescica: arriva il primo farmaco che può sostituire la chirurgia

UroGen Pharma Ltd

Legal

Press Releases

INVESTOR ALERT: Holzer & Holzer, LLC Reminds Investors of July 28, 2025 Lead Plaintiff Deadline in the UroGen Pharma Ltd. (URGN) Class Action – Investors With Significant Losses Encouraged to Contact the Firm

UROGEN DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds UroGen Pharma (URGN) Investors of the July 28th Deadline and Urges Investors to Inquire About Their Rights in Class Action Lawsuit

UroGen Announces Publication of Phase 3b Study Results Demonstrating the Feasibility of Home Instillation of ZUSDURI™ for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer in Reviews in Urology

UROGEN FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds UroGen Pharma (URGN) Investors of the July 28th Deadline and Urges Investors in to Inquire About Their Rights in Class Action Lawsuit

UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025

UroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Earnings

UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results

UroGen Pharma to Present at Upcoming Investor Conferences

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer

Arbutus Biopharma Corporation - Common Stock

Arbutus Biopharma

Akebia Therapeutics

AnaptysBio

ArriVent BioPharma

CareDx

Day One Biopharmaceuticals, Inc. - Common Stock

Day One Biopharmaceutical

Erasca

Geron

Gyre Therapeutics

Iovance Biotherapeutics, Inc. - Common Stock

Iovance Biotherapeutics

Inventiva S.A. - American Depository Shares

Inventiva

Kodiak Sciences

Keros Therapeutics

Kura Oncology

MeiraGTx Hldgs

Monopar Therapeutics

Myriad Genetics

Nurix Therapeutics

Olema Pharmaceuticals, Inc. - Common Stock

Olema Pharmaceuticals

Palvella Therapeutics, Inc. - Common Stock

Palvella Therapeutics

Rezolute

Savara

Tango Therapeutics

Tyra Biosciences

Vir Biotechnology

D. Boral Capital

Piper Sandler

HC Wainwright & Co.

Oppenheimer

Scotiabank

Comments

UroGen Pharma Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO